Sarepta Therapeutics Inc SRPT shares climbed 51% to $24.73 following the announcement of submission of rolling NDA for Eteplirsen. SunTrust Robinson Humphrey upgraded Sarepta Therapeutics from neutral to buy and raised the price target from $14.00 to $33.00. Share volume was 9.4 million, compared to an all-day average of 918,000
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in